Procaps Group
PROC

$2.07

2.36%

Market Cap: $234M

About: Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Employees: 5,500

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

273% more capital invested

Capital invested by funds: $271K [Q1] → $1.01M (+$738K) [Q2]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.08% more ownership

Funds ownership: 0.08% [Q1] → 0.16% (+0.08%) [Q2]

22% less funds holding

Funds holding: 9 [Q1] → 7 (-2) [Q2]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PROC.

See Analyst Rankings

Financial journalist opinion

Procaps Issues Shareholder Letter Update

MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, with updates on the Company's restructuring and strategic plan projects.

Procaps Issues Shareholder Letter Update

Procaps Issues Shareholder Letter

MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, addressing the current state of the business and outlining key strategic priorities for the Company.

Procaps Issues Shareholder Letter

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

Procaps Group Announces New Chairman

MIAMI & BARRANQUILLA, Columbia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that Mr. Ruben Minski has resigned from his role as Executive Chairman of the Board, effective June 30th. Mr. Minski will continue to serve as a member of the Board of Directors. Reflecting on his decision, Ruben stated: “This month marked six months since Jose Antonio Vieira assumed the role of CEO of.

Procaps Group Announces New Chairman

Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F.

Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F

Procaps Group Delays Filing of Annual Report on Form 20-F

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Delays Filing of Annual Report on Form 20-F.

Procaps Group Delays Filing of Annual Report on Form 20-F

Procaps Group Delays Filing of Annual Report on Form 20-F

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Delays Filing of Annual Report on Form 20-F.

Procaps Group Delays Filing of Annual Report on Form 20-F

Procaps Group – Notice to Shareholders

MIAMI & BARRANQUILLA, Colombia.--(BUSINESS WIRE)--Dear Shareholders, We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Shareholders of the Company scheduled for January 22, 2024, were incorrect. Notwithstanding the Company's diligent review of all relevant materials, a third party unilaterally included on the online version an inaccurate statement that the Board of Directors of the Company had recommended a vote in favo.

Procaps Group – Notice to Shareholders

Zacks Investment Research

Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates

Procaps Group, S.A. (PROC) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share.

Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates

Procaps Group Reports Third Quarter 2023 Results

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Third Quarter 2023 Results.

Procaps Group Reports Third Quarter 2023 Results

See News Rankings